MX2022011131A - Nuevo uso y metodo de tratamiento. - Google Patents

Nuevo uso y metodo de tratamiento.

Info

Publication number
MX2022011131A
MX2022011131A MX2022011131A MX2022011131A MX2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A MX 2022011131 A MX2022011131 A MX 2022011131A
Authority
MX
Mexico
Prior art keywords
treatment
new use
pharmaceutical composition
administration
active ingredient
Prior art date
Application number
MX2022011131A
Other languages
English (en)
Inventor
Martin Vidaeus
Hans Ageland
Ulf Björklund
Gerhard Garhöfer
Original Assignee
Redwood Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redwood Pharma Ab filed Critical Redwood Pharma Ab
Publication of MX2022011131A publication Critical patent/MX2022011131A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende como principio activo un hidrogel inversamente termorreversible, para la administración en el ojo de sujetos mamíferos. En particular, se refiere a una composición farmacéutica para su uso en, y a un método para, el tratamiento oftálmico de la enfermedad del ojo seco.
MX2022011131A 2020-03-12 2021-03-12 Nuevo uso y metodo de tratamiento. MX2022011131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162821 2020-03-12
PCT/EP2021/056314 WO2021180913A1 (en) 2020-03-12 2021-03-12 New use and method of treatment

Publications (1)

Publication Number Publication Date
MX2022011131A true MX2022011131A (es) 2022-11-14

Family

ID=69810711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011131A MX2022011131A (es) 2020-03-12 2021-03-12 Nuevo uso y metodo de tratamiento.

Country Status (12)

Country Link
US (1) US20230131227A1 (es)
EP (1) EP4117622A1 (es)
JP (1) JP2023517317A (es)
KR (1) KR20220152244A (es)
CN (1) CN115297839A (es)
AU (1) AU2021233161A1 (es)
BR (1) BR112022018060A2 (es)
CA (1) CA3170370A1 (es)
IL (1) IL296120A (es)
MX (1) MX2022011131A (es)
TW (1) TW202200208A (es)
WO (1) WO2021180913A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
LT2689774T (lt) 2011-03-21 2019-03-25 Broda Technologies Co., Ltd Atvirkščiai termiškai grįžtama hidrogelio kompozicija
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
EP3525885B1 (en) * 2016-10-12 2022-01-26 PS Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
CN108295318B (zh) * 2018-01-31 2021-07-06 西安泰科迈医药科技股份有限公司 一种温敏可注射型泪道栓及其制备方法

Also Published As

Publication number Publication date
IL296120A (en) 2022-11-01
JP2023517317A (ja) 2023-04-25
TW202200208A (zh) 2022-01-01
US20230131227A1 (en) 2023-04-27
WO2021180913A1 (en) 2021-09-16
EP4117622A1 (en) 2023-01-18
CA3170370A1 (en) 2021-09-16
KR20220152244A (ko) 2022-11-15
BR112022018060A2 (pt) 2022-10-25
AU2021233161A1 (en) 2022-09-29
CN115297839A (zh) 2022-11-04

Similar Documents

Publication Publication Date Title
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2011053801A3 (en) Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
WO2016042163A3 (en) Ophthalmic drug compositions
JP2019532931A (ja) 眼瞼炎の治療に使用するための医薬組成物
BRPI0608152A2 (pt) formulações para tratamento ocular
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
MX2013011314A (es) Tratamientos oftalmicos.
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
ATE428401T1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
RU2018114926A (ru) Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
EP4279063A3 (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2016060917A3 (en) Formulations for histatin therapeutics
BR112014009761B8 (pt) Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone
MX2023009352A (es) Metodos para la administracion oftalmica de roflumilast.
WO2021262916A8 (en) Pharmaceutical formulations of griseofulvin for long-term ocular delivery
MX2022011131A (es) Nuevo uso y metodo de tratamiento.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore